David Liu

Richard Conway, a vasculitis specialist, discusses pivotal findings from ACR 2024. Peter Nash delves into the role of JAK inhibitors, while Janet Pope reviews treatment strategies for polymyalgia rheumatica and giant cell arteritis. Eric Dian analyzes intriguing oral abstracts on rheumatoid arthritis, and David Liu emphasizes cardiovascular risks associated with treatments. They explore the safety of JAKs, advances in managing RA during COVID-19, and the efficacy of new therapies for PMR and GCA, showcasing innovative strategies for improving patient outcomes.

Joining the discussion are David Liu, a rheumatologist from Melbourne, and Akhil Sood, a fellow at Stanford with expertise in lupus treatment. They dive into groundbreaking studies from the ACR Annual Meeting, spotlighting promising results for Dapirulizumab in lupus care. The conversation shifts to new therapies and the clinical implications for lupus and advancements in AI for diagnosing inflammatory conditions. They also address the risks of steroid use in rheumatic diseases and the emerging management challenges faced by patients.